Keywords: Vivus, Qnexa, Obesity, Benefit/risk
Vivus leaps after releasing strong efficacy and safety data on obesity drug Qnexa
Article | 22 September 2010
USA-based Vivus (Nasdaq: VVUS) saw its shares jump 16% to $7.19 in early trading yesterday, after the company revealed positive top-line results ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
